These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15663999)

  • 1. Intervention thresholds for osteoporosis in the UK.
    Kanis JA; Borgstrom F; Zethraeus N; Johnell O; Oden A; Jönsson B
    Bone; 2005 Jan; 36(1):22-32. PubMed ID: 15663999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.
    Kanis JA; Johnell O; Oden A; Borgstrom F; Johansson H; De Laet C; Jönsson B
    Osteoporos Int; 2005 Jan; 16(1):6-14. PubMed ID: 15103452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intervention thresholds for osteoporosis.
    Kanis JA; Johnell O; Oden A; De Laet C; Oglesby A; Jönsson B
    Bone; 2002 Jul; 31(1):26-31. PubMed ID: 12110408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect and offset of effect of treatments for hip fracture on health outcomes.
    Jonsson B; Kanis J; Dawson A; Oden A; Johnell O
    Osteoporos Int; 1999; 10(3):193-9. PubMed ID: 10525710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of osteoporotic fractures: a method for setting intervention thresholds.
    Kanis JA; Oden A; Johnell O; Jonsson B; de Laet C; Dawson A
    Osteoporos Int; 2001; 12(5):417-27. PubMed ID: 11444092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.
    Borgström F; Johnell O; Kanis JA; Jönsson B; Rehnberg C
    Osteoporos Int; 2006 Oct; 17(10):1459-71. PubMed ID: 16847588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.
    Sander B; Elliot-Gibson V; Beaton DE; Bogoch ER; Maetzel A
    J Bone Joint Surg Am; 2008 Jun; 90(6):1197-205. PubMed ID: 18519311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Absolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosis].
    Harada A;
    Clin Calcium; 2007 Jul; 17(7):1029-34. PubMed ID: 17607069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effective osteoporosis treatment thresholds: the United States perspective.
    Tosteson AN; Melton LJ; Dawson-Hughes B; Baim S; Favus MJ; Khosla S; Lindsay RL;
    Osteoporos Int; 2008 Apr; 19(4):437-47. PubMed ID: 18292976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
    Jansen JP; Gaugris S; Bergman G; Sen SS
    Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study.
    Chang KP; Center JR; Nguyen TV; Eisman JA
    J Bone Miner Res; 2004 Apr; 19(4):532-6. PubMed ID: 15005838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of accuracy and cost effectiveness of clinical criteria and BUA for referral for BMD assessment by DXA in osteoporotic and osteopenic perimenopausal subjects.
    Langton CM; Langton DK; Beardsworth SA
    Technol Health Care; 1999; 7(5):319-30. PubMed ID: 10543417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A 10-year-review (1998 - 2007) on 3449 cases of osteoporotic hip fractures: trend of hospitalization and inpatient costs].
    Cheng ZA; Lin DK; Liu DB; Shen HY; Chen Q; Qiu QW; Liu SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Nov; 29(11):1128-31. PubMed ID: 19173940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of preventing hip fracture in the general female population.
    Kanis JA; Dawson A; Oden A; Johnell O; de Laet C; Jonsson B
    Osteoporos Int; 2001; 12(5):356-61. PubMed ID: 11444082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of osteoporotic hip fractures.
    Woratanarat P; Wajanavisit W; Lertbusayanukul C; Loahacharoensombat W; Ongphiphatanakul B
    J Med Assoc Thai; 2005 Oct; 88 Suppl 5():S96-104. PubMed ID: 16869109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
    Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
    Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The societal burden of osteoporosis in Sweden.
    Borgström F; Sobocki P; Ström O; Jönsson B
    Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.